Vofopitant
Vofopitant is a drug that belongs to the class of neurokinin 1 receptor antagonists. It is primarily used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
Pharmacology[edit]
Vofopitant acts by blocking the neurokinin 1 receptor, which is a key player in the emetic reflex. This receptor is activated by substance P, a neuropeptide involved in pain perception and the vomiting reflex. By blocking this receptor, Vofopitant prevents the activation of the vomiting reflex, thereby reducing the incidence of CINV.
Clinical Use[edit]
Vofopitant is used in combination with other antiemetic drugs for the prevention of acute and delayed CINV. It is particularly effective in patients receiving highly emetogenic chemotherapy regimens. The drug is usually administered orally, but can also be given intravenously.
Side Effects[edit]
Common side effects of Vofopitant include fatigue, constipation, and diarrhea. Less common side effects may include headache, dizziness, and insomnia. As with all drugs, patients should be monitored for any adverse reactions while taking Vofopitant.
Research[edit]
Research into the use of Vofopitant and other neurokinin 1 receptor antagonists is ongoing. Current studies are investigating the efficacy of these drugs in other conditions associated with nausea and vomiting, such as postoperative nausea and vomiting and gastroenteritis.
See Also[edit]
